Evidence map›Paper›PMID 41171468›Full record

ArticleWorld journal of urology2025

Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching.

Wencong Han, Kun Peng, Qi Shen, Shiwei Chen, Zejin Ou, Tai Kang, Xiaojun Yu, Jianbin Zhang, Zheng Zhang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Molecularly defined renal cell carcinomas.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wencong HanDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Kun PengDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Qi ShenDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Shiwei ChenDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Zejin OuDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Tai KangDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Xiaojun YuDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Jianbin ZhangShanxi Province Cancer Hospital; Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, China.
Zheng ZhangDepartment of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center., No.8 Xishiku Street, Xicheng District, Beijing, 100034, China. doczhz@aliyun.com.

Funding

Beijing Research Ward Excellent Program No. BRWEP2024W054070104National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) No.2024IR32
6 · The paper itself

Abstract

backgroundTFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare subtype of RCC. This study aims to compare the clinical characteristics and survival outcomes with clear cell RCC (ccRCC) and explore the feasibility of partial nephrectomy (PN) in early-stage TFE3-rRCC patients. MATERIALS AND PATIENTS: This retrospective cohort study included 62 patients with TFE3-rRCC who underwent surgical resection at Peking University First Hospital between 2016 and 2024. Propensity score matching (PSM) was applied to match TFE3-rRCC patients with ccRCC patients. Clinical characteristics and survival outcomes were compared between the two groups.

resultsThe median age of TFE3-rRCC patients at diagnosis was 33.0 years, with a female predominance (61.3%). The majority of patients were asymptomatic (61.3%). Before PSM, TFE3-rRCC patients were significantly younger and had a higher proportion of pT > 2 tumors compared to ccRCC patients (P < 0.01). After 1:2 PSM, survival outcomes in terms of progression-free survival (PFS) and overall survival (OS) were comparable between TFE3-rRCC and ccRCC in early-stage tumors. In patients with T > 2 tumors, a trend toward worse PFS was observed in the TFE3-rRCC group, though it did not reach statistical significance (P = 0.08). No significant differences in PFS and OS were observed between TFE3-rRCC and ccRCC for patients undergoing PN.

conclusionTFE3-rRCC should be stratified for a more accurate prognosis. Early-stage TFE3-rRCC demonstrates survival outcomes similar to those of ccRCC, and partial nephrectomy is a viable treatment approach for these patients.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, Renal CellGene RearrangementKidney NeoplasmsAdultFemaleHumansMaleMiddle AgedNeoplasm StagingNephrectomyPropensity ScoreRetrospective StudiesSurvival RateBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsTFE3 protein, humanClear cell renal cell carcinomaPartial nephrectomySurvival outcomesTFE3-rearranged renal cell carcinoma

Identifiers

PMID41171468
PMCPMC12578750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.